Healthy Volunteers
Conditions
Brief summary
This study is to evaluate the effect and tolerance of a thymol containing dietary supplement, Musclin, in healthy adults.
Detailed description
This study will be an open label, uncontrolled, ascending dose clinical trial to assess the tolerance and effect of orally ingested Musclin, 20 mg thymol per capsule, in healthy adult subjects. In addition, this study will evaluate whether Musclin has an effect on creatine kinase and myostatin levels. The study will aim to enroll 20 consenting men and women. Consented subjects will ingest 2 capsules of Musclin daily for 30 days and increase to 4 capsules daily for an additional 30 days . Physical assessments and biological samples will be collected at baseline (day 0) and at end of treatment (d 60). Surveys to include reported stamina and energy levels will be collected at baseline, prior to increased dosage (d 30) and end of treatment period. Risk to participants is expected to be minimal and will be outlined through an informed consent.
Interventions
DIETARY_SUPPLEMENTThymol
Musclin - a dietary supplement: 2 capsules (20 mg thymol per capsule) BID with a meal for 30 days increased to 4 capsules for an additional 30 days.
Sponsors
Innovus Pharmaceuticals, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Intervention model description
Open label, single arm, ascending dose
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Healthy volunteer \> 40 years (adult) 2. Systolic blood pressure 90-140 mmHg upon screening 3. Subject has provided written informed consent 4. Subject is willing to undergo the procedures outlined in this study 5. Subjects BMI is within 18-28. 6. Subjects of childbearing potential must use a hormonal method of birth control, single-barrier method or a double-barrier method of birth control throughout the study or be documented as medically sterile.
Exclusion criteria
1. Subject has clinically significant deviation from normal in any organ system. 2. Subject has a clinically significant deviation from normal in any laboratory test except high cholesterol. 3. Pregnant, breastfeeding, or planned pregnancy during the study duration. 4. Known liver, renal or muscle diseases. 5. History of hypertensive or currently taking anti-hypertensive medications. 6. Presence or history of specific heart conditions. 7. Currently taking anti-thyroid or thyroid replacement medications. 8. Currently taking any creatinine kinase lowering drug or supplement. 9. Use of investigational drug within the previous 30 days. 10. Use of herbal supplements, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within 2 weeks prior to initial dosing. 11. Known allergies or intolerance to ingredients in Musclin™ 12. Any condition which would interfere with the subject's ability to provide informed consent, to comply with study instructions, or which might confound the interpretation of the study results. \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with adverse events as a measure of tolerance | Day 60 (End of Study) | — |
| Change in creatinine kinase | Day 1(Baseline) to Day 60 (End of Study) | Change in creatinine kinase measured in U/L |
| Change in myostatin levels | Day 1(Baseline) to Day 60 (End of Study) | Change in myostatin will be measured by blood samples using ELISA method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in weight | Day 1(Baseline) to Day 60 (End of Study) | Effect of supplement on weight (lbs) |
| Change in cholesterol levels | Day 1(Baseline) to Day 60 (End of Study) | Effect of supplement on cholesterol levels |
| Number, type, and severity of adverse events | 60 days | — |
Countries
United States
Outcome results
None listed